secwatch / observer
8-K filed June 14, 2023, 7:59 PM ET ticker QTTB CIK 0001661998
other confidence high sentiment neutral materiality 0.10

Homology Medicines shareholders elect two Class II directors and ratify auditor at annual meeting

Q32 Bio Inc.

Key facts

Extracted from this filing and checked against the source text.

Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Q32 Bio Inc. shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the year ending December 31, 2023 at the 2023-06-14 meeting.

Proposal
auditor ratification
Outcome
passed
Meeting
2023-06-14
Exact text from the filing
Item 2 - Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023. Votes FOR Votes AGAINST Votes ABSTAINED Broker Non-Votes 44,765,597 108,239 691,660 0
View on SEC.gov
Shareholder Votes SEC 8-K Item 5.07 confidence 0.9

Q32 Bio Inc. shareholders approved Election of two Class II Directors to serve until the Company's 2026 Annual Meeting of Stockholders at the 2023-06-14 meeting.

Proposal
director election
Outcome
passed
Meeting
2023-06-14
Exact text from the filing
NOMINEE Votes FOR Votes WITHHELD Broker Non-Votes Steven Gillis, Ph.D. 32,246,621 2,619,932 10,698,943 Albert Seymour, Ph.D. 34,681,867 184,686 10,698,943
View on SEC.gov

Browse all shareholder votes →

Q32 Bio Inc. filing history →

Source: SEC EDGAR
accession 0001193125-23-166857
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.